Analyst Viewpoint
Surge in prevalence of neurological disorders & cancer owing to rise in number of individuals who smoke is driving the global brain cancer diagnostics industry. This escalating health concern necessitates the development and adoption of advanced diagnostic solutions to effectively address these challenges. Rise in awareness and increase in screening programs for brain cancer are the other factors propelling market expansion. Furthermore, technological advancements in non-invasive techniques are expected to bolster the global brain cancer diagnostics market size during the forecast period.
Development of more advanced, accurate, and efficient diagnostic technique offers lucrative opportunities to market players. Companies are focusing on development of non-invasive diagnostic tools that offer rapid and secure means to visualize the brain's internal structures.
Brain cancer diagnostics include a comprehensive array of medical procedures and tests designed to identify and assess the presence of brain tumors and other abnormalities within the brain. This diagnostic process is of paramount importance as it serves as the foundation for informed treatment decisions and ultimately influences patient outcomes.
Non-invasive techniques play a pivotal role in modern medicine, offering alternatives to invasive procedures such as brain biopsy. These techniques encompass both physical inspections of the body and advanced imaging modalities, particularly when it comes to the examination of the brain.
Computed tomography (CT) scans and magnetic resonance imaging (MRI) are the most widely used non-invasive imaging methods for brain cancer. These techniques provide rapid and secure means to visualize the brain's internal structures, enabling radiologists and healthcare professionals to identify various brain problems, track the progression of diseases, and plan surgical interventions.
Detecting and segmenting brain tumors is one of the most complex and critical tasks in medical imaging. Brain tumors are of diverse shapes and sizes, making it a challenging endeavor that often necessitates a substantial amount of data and information.
The global brain cancer diagnostics market demand has experienced robust growth in the past few years. This is ascribed to surge in prevalence of brain tumors, particularly malignant glioblastoma, and rise in awareness about early detection facilitated by government-backed screening programs.
Incidence of brain tumors is increasing as the global population continues to age. Moreover, persisting risk factors, such as smoking and environmental exposure, contribute to increase in demand for accurate diagnostic tools.
Glioblastoma, a particularly malignant form of brain tumor, exemplifies the urgency of early detection. This fast-growing and lethal condition underscores the critical need for swift diagnosis and intervention to enhance patient outcomes.
Increase in awareness about the importance of early detection and implementation of government-backed screening programs plays a pivotal role in bolstering global brain cancer diagnostics market growth.
Public awareness campaigns have shed light on the significance of identifying brain tumors at an early, more treatable stages. These initiatives encourage individuals to proactively seek regular check-ups and screenings, not only enhancing the chances of early diagnosis, but also promoting general health consciousness.
Increase in awareness has enabled more individuals to take proactive steps to include brain cancer diagnostics in their healthcare routines. This not only benefits individual patients but also leads to broader public health benefits by reducing the overall burden of advanced-stage brain cancers on healthcare systems.
Around 12,288 new cases of brain and CNS tumors are diagnosed in the U.K. each year, with brain tumor ranking as the ninth most common malignancy, accounting for 3% of all new cancer cases. Similar trends are observed in Australia, where thousands of new brain cancer cases are reported annually.
Technological advancements in non-invasive diagnostic techniques is driving the global brain cancer diagnostics industry. These innovations not only contribute to the ongoing demand for brain cancer diagnostics, but also hold great promise for the future of healthcare.
Development of noninvasive diagnostic techniques is a major factor bolstering the global brain cancer diagnostics market value. These techniques offer a patient-friendly approach that reduces the need for invasive procedures such as biopsies.
Non-invasive methods not only minimize patient discomfort, but also enhance safety, early detection, and diagnostic accuracy. These are becoming increasingly important in improving the patient experience and encouraging more individuals to undergo regular brain cancer screenings. Moreover, non-invasive techniques are instrumental in detecting tumors in the early, more treatable stages, leading to better patient outcomes.
In terms of diagnostic technique, the imaging techniques segment dominated the global brain cancer diagnostics market. This is ascribed to increase in reliance on imaging technologies in the diagnosis of a brain cancer. Magnetic Resonance Imaging (MRI) is a major medical imaging technique in radiology, contributing to the production of detailed anatomical images and insights into the body's physiological processes.
Rise in prevalence of brain cancer cases is also expected to propel demand for brain tumor diagnostics during the forecast period. In February 2023, Case Western Reserve University received a substantial grant of US$ 3 Mn to advance novel MRI technology and software specifically designed for brain tumor diagnosis. This development holds significant promise as it has the potential to revolutionize the field of brain cancer diagnostics.
Utilization of advanced MRI technology, along with specialized software, can provide highly detailed images and data that are essential for personalized treatment planning. This, in turn, can significantly improve patient outcomes by enabling healthcare providers to tailor treatments to the unique characteristics of each patient's brain tumor.
Integration of cutting-edge MRI technology and software advancements exemplifies the commitment of the healthcare and research community to continuously enhance the capabilities of diagnostic tools for brain cancer. This effort not only underscores the importance of MRI but also highlights the potential for innovative technologies to contribute to improved patient care.
Based on brain cancer type, the gliomas segment is expected to account for the largest global brain cancer diagnostics market share during the forecast period. This is ascribed to wide spectrum of subtypes of gliomas and their impact on brain health. Gliomas are characterized by their highly infiltrative nature, which affects the surrounding brain tissue, making their accurate diagnosis and monitoring crucial.
Glioblastoma is the most malignant subtype of glioma. This aggressive form of brain cancer grows rapidly and is associated with a poor prognosis, emphasizing the urgency of early and precise diagnosis.
High prevalence and diverse nature of gliomas necessitate advanced and specialized diagnostic approaches for accurate characterization and tailored treatment planning. The global brain cancer diagnostics market, therefore, continues to place strong emphasis on glioma diagnostics, given their clinical significance and their impact on the lives of patients.
This underscores the importance of ongoing research, technological advancements, and multidisciplinary collaboration in the field of brain cancer diagnostics to address the challenges posed by gliomas effectively.
In terms of end-user, the hospitals segment is likely to dominate the global brain cancer diagnostics market during the forecast period. Hospitals play a pivotal role in accurate and early diagnosis of brain cancer.
The healthcare landscape, characterized by increase in prevalence of brain tumors and the critical need for timely and precise diagnostics, places hospitals at the forefront of this essential endeavor.
Hospitals have state-of-the-art equipment, including MRI, CT, PET, various specialized imaging technologies; and a diverse team of healthcare professionals, such as radiologists, neurosurgeons, oncologists, and pathologists.
These facilities are crucial for providing detailed scans and expert interpretation, making them a primary destination for patients seeking accurate brain cancer assessment. This multidisciplinary approach ensures a comprehensive evaluation of brain cancer cases, allowing for individualized and accurate diagnoses.
According to brain cancer diagnostics market analysis, North America dominated the global industry in 2022. This is ascribed to increase in incidence of brain cancer cases across the region. High prevalence of brain cancer necessitates advanced diagnostic tools to improve early detection and treatment outcomes.
Ongoing clinical trials conducted by multiple companies in North America also contribute to market expansion. These trials aim to develop more effective treatments, emphasizing the importance of early and accurate diagnosis as the first step in the management of brain cancer.
Aa per brain cancer diagnostics market forecast, the industry in Asia Pacific is driven by rise in incidence of brain cancer, improved diagnostic technologies, and growing awareness about early cerebral tumor detection. Moreover, presence of key players such as GE Healthcare and Siemens Healthineers offering innovative diagnostic solutions is expected to fuel the brain cancer diagnostics industry revenue in Asia Pacific during the forecast period. Furthermore, increase in healthcare investment, rise in research & development activities, and surge in elderly population are driving market growth in the region.
The global brain cancer diagnostics market is fragmented, with the presence of large number of players. Companies are focusing investing in R&D and merger & acquisition in order to increase market share and presence.
GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Illumina, Inc., Hologic, Inc., Agilent Technologies, and Bio-Rad Laboratories are the prominent players in the market.
Each of these players has been profiled in the brain cancer diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 1.5 Bn |
| Forecast (Value) in 2031 | More than US$ 2.5 Bn |
| Growth Rate (CAGR ) | 5.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
It was valued at US$ 1.5 Bn in 2022
It is projected to reach more than US$ 2.5 Bn by 2031
It is anticipated to grow at a CAGR of 5.9% from 2023 to 2031
Surge in prevalence of brain tumors and increase in awareness & rise in screening programs
North America is expected to account for largest share during the forecast period.
GE Healthcare, Siemens Healthineers, Philips Healthcare, Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Illumina, Inc., Hologic, Inc., Agilent Technologies, and Bio-Rad Laboratories
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Brain Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Brain Cancer Diagnostics Market Analysis and Forecasts, 2023–2031
5. Key Insights
5.1. Brain Tumor Epidemiology
5.2. Current Trends in Diagnostic and Therapeutic Imaging of Brain Tumors
5.3. Technological advancements in cancer diagnostics
5.4. COVID-19 Impact Analysis
6. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Diagnostic Technique
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Diagnostic Technique, 2023–2031
6.3.1. Imaging Techniques
6.3.1.1. Magnetic Resonance Imaging (MRI)
6.3.1.2. Computed Tomography (CT) Scan
6.3.1.3. PET Scan or PET-CT Scan
6.3.1.4. (SPECT) Scan
6.3.2. Tissue Sampling/Biopsy
6.3.3. Molecular Diagnostics
6.3.4. Others
6.4. Market Attractiveness Analysis, by Diagnostic Technique
7. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Brain Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
7.3.1. Gliomas
7.3.2. Meningiomas
7.3.3. Pituitary Tumors
7.3.4. Others
7.4. Market Attractiveness Analysis, by Brain Cancer Type
8. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2023–2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Cancer Hospitals/Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Brain Cancer Diagnostics Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Brain Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
10.2.1. Imaging Techniques
10.2.1.1. Magnetic Resonance Imaging (MRI)
10.2.1.2. Computed Tomography (CT) Scan
10.2.1.3. PET Scan or PET-CT Scan
10.2.1.4. (SPECT) Scan
10.2.2. Tissue Sampling/Biopsy
10.2.3. Molecular Diagnostics
10.2.4. Others
10.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
10.3.1. Gliomas
10.3.2. Meningiomas
10.3.3. Pituitary Tumors
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2023–2031
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Cancer Hospitals/Centers
10.5. Market Value Forecast, by Country, 2023–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Diagnostic Technique
10.6.2. By Brain Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Brain Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
11.2.1. Imaging Techniques
11.2.1.1. Magnetic Resonance Imaging (MRI)
11.2.1.2. Computed Tomography (CT) Scan
11.2.1.3. PET Scan or PET-CT Scan
11.2.1.4. (SPECT) Scan
11.2.2. Tissue Sampling/Biopsy
11.2.3. Molecular Diagnostics
11.2.4. Others
11.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
11.3.1. Gliomas
11.3.2. Meningiomas
11.3.3. Pituitary Tumors
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2023–2031
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Cancer Hospitals/Centers
11.5. Market Value Forecast, by Country/Sub-region, 2023–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Diagnostic Technique
11.6.2. By Brain Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Brain Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
12.2.1. Imaging Techniques
12.2.1.1. Magnetic Resonance Imaging (MRI)
12.2.1.2. Computed Tomography (CT) Scan
12.2.1.3. PET Scan or PET-CT Scan
12.2.1.4. (SPECT) Scan
12.2.2. Tissue Sampling/Biopsy
12.2.3. Molecular Diagnostics
12.2.4. Others
12.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
12.3.1. Gliomas
12.3.2. Meningiomas
12.3.3. Pituitary Tumors
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2023–2031
12.4.1. Hospitals
12.4.2. Diagnostic Laboratories
12.4.3. Cancer Hospitals/Centers
12.5. Market Value Forecast, by Country/Sub-region, 2023–2031
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Diagnostic Technique
12.6.2. By Brain Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Brain Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
13.2.1. Imaging Techniques
13.2.1.1. Magnetic Resonance Imaging (MRI)
13.2.1.2. Computed Tomography (CT) Scan
13.2.1.3. PET Scan or PET-CT Scan
13.2.1.4. (SPECT) Scan
13.2.2. Tissue Sampling/Biopsy
13.2.3. Molecular Diagnostics
13.2.4. Others
13.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
13.3.1. Gliomas
13.3.2. Meningiomas
13.3.3. Pituitary Tumors
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2023–2031
13.4.1. Hospitals
13.4.2. Diagnostic Laboratories
13.4.3. Cancer Hospitals/Centers
13.5. Market Value Forecast, by Country/Sub-region, 2023–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Diagnostic Technique
13.6.2. By Brain Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Brain Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnostic Technique, 2023–2031
14.2.1. Imaging Techniques
14.2.1.1. Magnetic Resonance Imaging (MRI)
14.2.1.2. Computed Tomography (CT) Scan
14.2.1.3. PET Scan or PET-CT Scan
14.2.1.4. (SPECT) Scan
14.2.2. Tissue Sampling/Biopsy
14.2.3. Molecular Diagnostics
14.2.4. Others
14.3. Market Value Forecast, by Brain Cancer Type, 2023–2031
14.3.1. Gliomas
14.3.2. Meningiomas
14.3.3. Pituitary Tumors
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2023–2031
14.4.1. Hospitals
14.4.2. Diagnostic Laboratories
14.4.3. Cancer Hospitals/Centers
14.5. Market Value Forecast, by Country/Sub-region, 2023–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Diagnostic Technique
14.6.2. By Brain Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2021)
15.3. Company Profiles
15.3.1. GE Healthcare
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Siemens Healthineers
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Philips Healthcare
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Thermo Fisher Scientific
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Roche Diagnostics
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Abbott Laboratories
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. Illumina, Inc.
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. Hologic, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
15.3.9. Agilent Technologies
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Strategic Overview
15.3.9.5. SWOT Analysis
15.3.10. Bio-Rad Laboratories
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. Strategic Overview
15.3.10.5. SWOT Analysis
List of Tables
Table 01: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 02: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 03: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 04: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 06: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 07: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 08: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2023–2031
Table 09: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 10: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 11: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 12: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 13: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 14: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 15: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 16: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 17: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 18: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 19: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 20: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 21: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Diagnostic Technique, 2023–2031
Table 22: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Brain Cancer Type, 2023–2031
Table 23: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2023–2031
Table 24: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
List of Figures
Figure 01: Global Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031
Figure 02: Global Brain Cancer Diagnostics Market Value Share, by Diagnostic Technique 2023
Figure 03: Global Brain Cancer Diagnostics Market Value Share, by Brain Cancer Type 2023
Figure 04: Global Brain Cancer Diagnostics Market Value Share, by End-user 2023
Figure 05: Global Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 06: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Imaging Techniques 2023–2031
Figure 07: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Tissue Sampling/Biopsy 2023–2031
Figure 08: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Molecular Diagnostics 2023–2031
Figure 09: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Others 2023–2031
Figure 10: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031
Figure 11: Global Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 12: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Gliomas 2023–2031
Figure 13: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Meningiomas 2023–2031
Figure 14: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Pituitary Tumors 2023–2031
Figure 15: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Others 2023–2031
Figure 16: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031
Figure 17: Global Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 18: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals 2023–2031
Figure 19: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories 2023–2031
Figure 20: Global Brain Cancer Diagnostics Market Revenue (US$ Mn), by Cancer Hospitals/Centers 2017–2032
Figure 21: Global Brain Cancer Diagnostics Market Value Share Analysis, by Region 2023 and 2031
Figure 22: Global Brain Cancer Diagnostics Market Attractiveness Analysis, by Region 2023–2031
Figure 23: North America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031
Figure 24: North America Brain Cancer Diagnostics Market Value Share Analysis, by Country 2023 and 2031
Figure 25: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Country 2023–2031
Figure 26: North America Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 27: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031
Figure 28: North America Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 29: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031
Figure 30: North America Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 31: North America Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031
Figure 32: Europe Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031
Figure 33: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 34: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 36: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031
Figure 37: Europe Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 38: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031
Figure 39: Europe Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 40: Europe Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031
Figure 41: Asia Pacific Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031
Figure 42: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 43: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 44: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 45: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031
Figure 46: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 47: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031
Figure 48: Asia Pacific Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 49: Asia Pacific Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031
Figure 50: Latin America Brain Cancer Diagnostics Market Value (US$ Mn) Forecast 2023–2031
Figure 51: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 52: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 53: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 54: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Technique 2023–2031
Figure 55: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 56: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by Brain Cancer Type 2023–2031
Figure 57: Latin America Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 58: Latin America Brain Cancer Diagnostics Market Attractiveness Analysis, by End-user 2023–2031
Figure 59: Middle East & Africa Brain Cancer Diagnostics Market Value (US$ Mn) 2023–2031
Figure 60: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Country 2023 and 2031
Figure 61: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Country 2023–2031
Figure 62: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Diagnostic Technique 2023 and 2031
Figure 63: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Diagnostic Technique 2023–2031
Figure 64: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by Brain Cancer Type 2023 and 2031
Figure 65: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness , by Brain Cancer Type 2023–2031
Figure 66: Middle East & Africa Brain Cancer Diagnostics Market Value Share Analysis, by End-user 2023 and 2031
Figure 67: Middle East & Africa Brain Cancer Diagnostics Market Attractiveness, by End-user 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Brain Cancer Diagnostics Market
*86 figures and 60 tables includes